Monitor for any subsequent filings that may indicate further executive changes or financial reporting delays, though the internal promotion of the CFO to principal accounting officer suggests operational continuity.
Price Chart
Executive Summary
TScan Therapeutics announced the resignation of Leiden Dworak as Vice President of Finance and principal accounting officer, effective April 10, 2026. Jason A. Amello, the company's CFO, has been appointed as the new principal accounting officer without additional compensation.
Key Facts
- Leiden Dworak resigned as Vice President of Finance and principal accounting officer effective April 10, 2026.
- Jason A. Amello, current CFO and principal financial officer, was appointed as principal accounting officer effective April 10, 2026.
- No disagreements were reported between the company and Mr. Dworak regarding operations, policies, or practices.
- Mr. Amello will not receive additional compensation for taking on the expanded role.
Financial Impact
No immediate financial impact; no change in compensation or organizational costs.
Risk Factors
- Potential transitional risk in financial oversight during the role transfer, though mitigated by Amello's existing CFO position.
- Limited insight into Dworak's reasons for departure beyond 'resignation,' though no reported disagreements reduce immediate concern.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-138973 |
| Document: 0001193125-26-138973-index-headers.html | 0001193125-26-138973 |
| Document: 0001193125-26-138973-index.html | 0001193125-26-138973 |
| Document: 0001193125-26-138973.txt | 0001193125-26-138973 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 8-K | $0.3204 $0.3119 | ▼ −2.65% | ▼ −2.43% | $0.3189 (−0.47%) |
Sep 2, 2026 4w ago | 8-K | $0.3810 $0.3179 | ▲ +16.56% | ▲ +15.60% | $0.3189 (+16.30%) |
Aug 18, 2026 6w ago | 8-K | $0.7500 $0.7774 | ▼ −3.65% | ▼ −4.04% | $0.3189 (+57.48%) |
Aug 12, 2026 7w ago | 8-K | $0.7730 $0.7500 | ▲ +2.98% | ▲ +2.53% | $0.3189 (+58.75%) |
Aug 12, 2026 7w ago | Press Release | $0.7730 $0.7500 | ▲ +2.98% | ▲ +2.53% | $0.3189 (+58.75%) |
Jun 22, 2026 14w ago | 8-K | $0.8651 $0.9775 | ▲ +12.99% | ▲ +13.45% | $0.3189 (−63.14%) |
Jun 22, 2026 14w ago | Press Release | $0.8651 $0.9688 | ▲ +11.99% | ▲ +14.06% | $0.3189 (−63.14%) |
May 6, 2026 21w ago | 8-K | $1.25 $1.15 | ▼ −8.00% | ▼ −9.13% | $0.3189 (−74.49%) |
Apr 2, 2026 26w ago | 8-K | $1.01 $1.05 | ▲ +3.96% | ▲ +0.34% | $0.3189 (−68.43%) |
Mar 4, 2026 30w ago | Press Release | $1.08 $1.15 | ▲ +6.48% | ▲ +7.81% | $0.3189 (−70.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access